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Summary
Chronic airway infection with Pseudomonas aeruginosa (PA) causes morbidity and mortality in
patients with cystic fibrosis (CF). Additional anti-PA therapies are needed to improve health status
and health-related quality of life. AIR-CF3 was an international 18-month, open-label study to
evaluate the safety and efficacy of repeated courses of aztreonam for inhalation solution (AZLI,
now marketed as Cayston®) in patients aged ≥6 years with CF and PA infection who previously
participated in one of two Phase 3 studies: AIR-CF1 or AIR-CF2. Patients received up to nine
courses (28 days on/28 days off) of 75 mg AZLI two (BID) or three times daily (TID) based on
randomization in the previous trials. 274 patients, mean age 28.5 years (range: 8–74 years),
participated. Mean treatment adherence was high (92.0% BID group, 88.0% TID group).
Hospitalization rates were low and adverse events were consistent with CF With each course of
AZLI, FEV1 and scores on the Cystic Fibrosis Questionnaire-Revised Respiratory Symptomscale
improved and bacterial density in sputum was reduced. Benefits waned in the 28 days off therapy,
but weight gain was sustained over the 18months. There were no sustained decreases in PA
susceptibility. A dose response was observed; AZLI TID-treated patients demonstrated greater
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improvements in lung function and respiratory symptoms over 18 months. Repeated intermittent
28-day courses of AZLI treatment were well tolerated. Clinical benefits in pulmonary function,
health-related quality of life, and weight were observed with each course of therapy. AZLI is a
safe and effective new therapy in patients with CF and PA airway infection.
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INTRODUCTION
Chronic, suppressive antibiotic therapy has become the standard of care for patients with
cystic fibrosis (CF) and chronic Pseudomonas aeruginosa (PA) infection.1 Inhaled
antibiotics may be preferred to systemic antibiotics in the treatment of chronic
endobronchial infection in patients with CF because of better tolerability, increased airway
concentrations of antibiotic to ventilated regions of the lung compared with systemic
administration, and the minimization of systemic effects and drug-drug interactions.
Aztreonam for inhalation solution (AZLI) is an aerosolized formulation of the monobactam
antibiotic, aztreonam, with lysine as an excipient.2 The intravenous (IV) aztreonam
formulation contains arginine, which can cause airway inflammation after repeated
inhalation in patients with CF.3,4
Two published placebo-controlled studies of AZLI showed benefit in patients with CF and
PA infection.5,6 AIR-CF1 demonstrated that a 28-day course of AZLI given three times
daily (TID) resulted in improved respiratory symptoms as measured by the cystic fibrosis
questionnaire-revised (CFQ-R), increased forced expiratory volume in 1 sec (FEV1), and
decreased bacterial density in sputum.6 AIR-CF2 showed that a 28-day course of AZLI
immediately following a 28-day course of tobramycin inhalation solution (TIS) delayed the
timeto-need for additional inhaled or systemic anti-PA antibiotics.5 It also showed an
increase in FEV1 and improved respiratory symptom scores on the CFQ-R at the end of the
AZLI treatment course compared to placebo. No safety concerns emerged with the two
short-term studies. However, the safety and efficacy of long-term AZLI therapy remained
untested.
The current protocol, AIR-CF3, was an 18-month openlabel study to evaluate the safety and
efficacy of two dose regimens of AZLI in patients with CF and PA airway infection using
the accepted treatment paradigm of month on/month off therapy.7
MATERIALS AND METHODS
Study Design
Patients who previously participated in either AIR-CF1 or AIR-CF2 were eligible to enroll
in this open-label, follow-on study conducted at 71 CF centers (Australia, Canada, New
Zealand, US; August 2005–November 2008). Patients received up to 9 courses, 28 days of
AZLI followed by 28 days off therapy. Additional specialized CF care continued throughout
the study period as prescribed by each patient’s primary treating CF care provider. The
original protocol was designed to have patients receive two courses with an optional third
course; the protocol was amended to extend the treatment period to nine courses in order to
provide long-term safety and efficacy data and satisfy clinical demand for continued
therapy. Patients attended up to 20 scheduled investigational visits. Patients received open-
label AZLI 75 mg TID (via an investigational nebulizer (PARI eFlow® Electronic
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Nebulizer, branded Altera® in the European Union, manufactured by PARI Innovative
Manufacturers, Midlothian, Virginia),8 except for those who had originally been randomized
to the 75mg twice daily (BID) dosing regimen arm of AIR-CF2. All 85 patients receiving
BID therapy in AIR-CF3 were from the BID arm of the AIR-CF2 study. Patients were off
AIR-CF1 or AIR-CF2 study drug for at least 28 days before starting AZLI in AIR-CF3. The
drug-free interval varied and may have been longer at some sites due to prolonged
Institutional Review Board/Ethics Committee review timelines. Patients were instructed to
use an inhaled bronchodilator prior to each dose of AZLI. The bronchodilator used was
based on each patient’s routine (i.e., long-acting versus short-acting) and used to avoid any
potential bronchospasm associated with inhaled medication use. Patients were also
instructed to take the doses of AZLI a minimum of 4 hr apart. Patients attended a follow-up
visit 28 days after completing the last course of AZLI.
A physical exam was performed at screening, subsequent visits, and at follow up.
Spirometry (American Thoracic Society standards) was performed at every visit before, and
30 minutes after, receiving a dose of AZLI.9 FEV1 % predicted values were calculated using
the Knudson equation.10 The age-appropriate CFQ-R was administered at each study visit
prior to collection of any other data.11 Study medication was dispensed at the beginning of
each course of treatment; used and unused vials were collected to assess treatment
adherence.
This study was conducted in compliance with the Declaration of Helsinki, the International
Conference on Harmonization guideline for Good Clinical Practices, and the applicable
regulations for each participating country. Institutional Review Boards (US) and Ethics
Committees (Canada, Australia, and New Zealand) approved the study for each site, and all
patients or their guardians provided written informed consent or assent prior to any study
procedures. The ClinicalTrials.gov accession number is NCT00128492.
Study Population
Patients were ≥6 years of age with a documented CF diagnosis (as evidenced by one or more
clinical features consistent with the CF phenotype and one or more of the following criteria:
sweat chloride ≥60 mEq/L by quantitative pilocarpine iontophoresis test, or two well
characterized mutations in the cystic fibrosis transmembrane conductance regulator (CFTR)
gene, or abnormal nasal potential difference).12 All patients had completed either Study
AIR-CF1 or AIR-CF2 or had withdrawn from either of these studies due to need for
antipseudomonal antibiotics or due to an adverse event (AE) unrelated to study medication
tolerability.
Exclusion criteria included: the use of any investigational medication or device between the
last visit of Studies AIR-CF1 or AIR-CF2 and Visit 1 (baseline) of AIR-CF3; concurrent
participation in a study of another investigational medication or device; current oral
corticosteroid use equivalent to> 10 mg prednisone daily; airway cultures yielding
Burkholderia cepacia complex (previous 2 years); daily continuous oxygen supplementation
of>2 L/min at night; inability to tolerate study medication in Studies AIR-CF1 or AIR-CF2;
monobactam antibiotic hypersensitivity; intolerance to inhaled short-acting β2-agonists;
aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >5 times upper limit of
normal at most recent test prior to enrolling in AIR-CF3; pregnancy; lactation; or, in the
opinion of the investigator, medical or psychiatric illness interfering with study
participation.
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Adverse events and changes in clinical laboratory values, vital signs, and airway reactivity
were monitored. Worsening CF symptoms were classified as treatment-emergent adverse
events.
Disease-Related Endpoint Measures
FEV1 was recorded at all scheduled and unscheduled visits.
The CFQ-R was administered at baseline and every visit thereafter prior to other study
procedures and AZLI treatment. The endpoint was change in respiratory symptoms from
baseline, assessed with the CFQ-R Respiratory Symptom (CFQ-R-Respiratory) scale (range
of scores: 0–100; higher scores indicate fewer symptoms). The minimal clinically important
difference (MCID) corresponds to the smallest change in symptoms that a patient can detect
and is used to interpret responses to patient-reported outcomes(PROs).13,14 An MCID score
of five was used in previous studies;5,6 however, a score of 4 has been determined for the
CFQ-R-Respiratory scale in stable patients.11 Thus four-point change in scores reflected
improved or worsened respiratory symptoms as reported by patients.
The following non-respiratory quality of life domains were measured by the CFQ-R on a
standardized scale of 0–100 by both the patient and parent/caregiver: Physical Functioning,
Emotional Functioning, Social Functioning, Body Image, Eating Disturbances, Role
Limitations/ School Performance, Weight, Vitality, Treatment Burden, Digestive Symptoms,
and Health Perceptions.
Other disease-related endpoints included sputum PA density (colony forming units (CFU)/g
sputum, log10 transformed), the percent of days and number of days hospitalized, time to
first respiratory hospitalization, percent change in weight, and the time to use of IV
antibiotics.
Microbiology Endpoints
Sputum samples were collected at all visits for qualitative and quantitative culture for PA,
Burkholderia spp., Stenotrophomonas maltophilia, Achromobacter xylosoxidans,
Staphylococcus aureus, Candida spp., and Aspergillus spp. If a patient was unable to
produce sputum, an oropharyngeal swab was collected for qualitative culture only.
Microbiologic testing and analyses were conducted at two central laboratories: Covance
Central Laboratory Services (for specimens collected in North America); and SydPath
Central Laboratory (for specimens collected in Australia/New Zealand). Sputum and swab
specimens were collected prior to the in-clinic administration of AZLI and at least 4 hr after
an at-home AZLI administration. Sputum PA density (CFU/g sputum) was determined using
serial sputum dilutions plated onto MacConkey agar. The minimum inhibitory concentration
(MIC) of aztreonam to PA isolated from subject specimens was determined using a
microbroth dilution technique. Twofold dilutions of aztreonam in Mueller Hinton broth
spanned from 2,048 to 1 µg/ml. A ≥4-fold change in MIC50 or MIC90 from the baseline
value was considered an increase or decrease.15 The presence of methicillinsensitive
(MSSA) and methicillin-resistant (MRSA) S. aureus was determined by testing the
susceptibility of S. aureus isolates to cefoxitin.16
Statistical Analyses
Descriptive statistics for all patients receiving ≥ 1 dose of AZLI were summarized for the
safety, microbiology, and disease-related endpoints. No formal hypothesis tests were
planned.
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The percent of patients experiencing at least one AE was summarized.
Percent changes from baseline in FEV1 percent predicted and actual changes from baseline
in CFQ-R-Respiratory scores and log10 PA CFUs in sputum were summarized.
Rate of hospitalizations were calculated as the total number of hospitalizations divided by
the sum total of years patients were on study. The time to first respiratory hospitalization
and the time to first use of IV antipseudomonal antibiotics were summarized by regimen
based on Kaplan–Meier analyses. Actual changes from baseline in weight (kg) were
summarized for the BID and TID regimens.
Statistical analyses used Statistical Analysis Software version 9.1 (SAS®, SAS Institute Inc.,
Cary, NC).
RESULTS
Two hundred seventy-four patients were enrolled; 85 patients received AZLI BID and 189
patients received AZLI TID. Of the 274 patients enrolled, 195 patients (71.2%; Fig. 1)
completed the study: 26 patients (18 in the BID group and 8 in the TID group) completed
the study after 3 planned treatment courses (Visit 7), prior to the trial extension; 166 (60.6%)
patients completed nine planned courses (Visit 20).
Drop out rates were similar for pediatric (25%) versus adult (30%) patients. The most
common reason for discontinuation was personal or administrative reasons (32 patients
[11.7%]) followed by adverse events judged by the investigator to be unrelated to the study
drug (11 patients [4.0%]). The remaining reasons for discontinuation included: study drug
intolerance (adverse event) (10 patients [3.6%]); the patient being lost to followup (6
patients [2.2%]), adverse events related to the study drug (5 patients [1.8%]), nonadherence
to study protocol (5 patients 1.8%]), other reasons (9 patients [3.3%]), and 1 death judged by
the investigator to be unrelated to study drug.
Patient Characteristics
Mean age was 28.5 years (range: 8–74 years) and most patients (79.9%) were ≥18 years of
age (Table 1). At baseline, mean FEV1 % predicted was 55.6% and the mean CFQ-R-
Respiratory score was 61.9. Concomitant medications used by ≥40% of patients in either
group at baseline included vitamins (91.2%), pancreatic enzymes (88.0%), salbutamol
(84.7%), dornase alfa (79.9%), fluticasone propionate with salmeterol xinafoate (55.5%),
and azithromycin (53.6%). Hypertonic saline was used by 16.8% of patients. Of these
concomitant medications, the use of fluticasone propionate with salmeterol xinafoate and
azithromycin were different (≥5%) between the BID and TID groups (60.0% vs. 53.4% and
60.0% vs. 50.8%, respectively). Over the course of the study 51.5% of subjects had at least
one course of inhaled tobramycin (Table 2). For patients administered tobramycin during the
study, the median number of days on inhaled tobramycin was 78 days.
Safety
Treatment-emergent respiratory adverse events reported with an incidence rate ≥10% are
summarized in Table 3. Non-respiratory events reported for ≥30% of BID- or TID-treated
patients were pyrexia (45.9% and 45.5%), fatigue (37.6% and 43.9%), decreased appetite
(30.6% and 45.5%), and headache (31.8% and 32.3%, respectively). The most common
adverse events were ascribed to baseline disease and included cough (89.4%) and productive
cough (80.3%). Over the 18-month study, serious adverse events occurred in 44.7% of BID-
treated patients and 52.4% of TID-treated patients; respiratory symptoms were the primary
cause of serious adverse events.
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Clinically significant changes in vital signs or mean clinical laboratory values were not
observed. There were no notable changes overall in heart rate, blood pressure, or respiratory
rate related to AZLI treatment.
Disease-Related Endpoints
Analyses of the disease related endpoints, change from baseline FEV1 percent predicted,
FEV1 absolute volume, CFQ-R-Respiratory scores, and density of PA in sputum, are
presented in Table 4. Comparing the BID to TID group revealed an apparent dose response
benefit. In both regimens, patients showed mean improvement from Visit 1 (baseline) at the
end of each treatment course, and a return toward baseline at the end of the off-treatment
intervals. For treatment courses 1–9, percent change in FEV1 (L) was positive at the end of
each on-drug course, and generally a greater response was observed for the TID regimen.
Additional pulmonary function measurements were obtained (forced vital capacity [FVC]
and forced expiratory flow from 25% to 75% of the FVC [FEF25–75]). For FVC, mean
change from baseline ranged from − 1.40% to 5.39% (BID) and from 0.97% to 6.18%
(TID). For FEF25–75, mean change from baseline ranged from −4.20% to 16.05% (BID) and
from −5.02% to 14.14% (TID). For the on-treatment months, the mean increase in CFQ-R-
Respiratory score was >4, the established MCID.17 No response shift on the CFQ-R
Respiratory Symptom scale (e.g., resetting symptom ratings to baseline) was observed over
18 monthly administrations, and no testing effects (remembering and recreating answers
from last test) were apparent.
Changes on other symptom scales of the CFQ-R were consistent with treatment benefit, with
greater improvements seen for the TID group compared to the BID group (data not shown).
In the TID group, mean improvements from baseline for the Physical Functioning, Vitality
and Health Perceptions domains tended to be greater during each of the intervals when the
patient was on treatment and less during each of the intervals when the patient was off
treatment; however, no MCID has been determined for these domains. For the TID group,
mean scores for the Weight domain tended to be above baseline throughout the nine
treatment courses. Of note, there was a small mean decline from baseline in the Treatment
Burden score after nine treatment courses; however, the change (worsening) was similar for
both treatment regimens. Absolute changes from baseline for the remaining domains
(emotional functioning, social functioning, body image, eating disturbances, role limitations/
school performance and digestion) were variable and showed no apparent dose response.
Hospitalization Rates and Use of Systemic Antipseudomonal Therapy
One hundred thirty-one patients (47.8%) were hospitalized at least once during the study,
and the overall hospitalization rate per patient year was 0.897 (Table 5). The most frequent
reason for hospitalization was the worsening or appearance of lower respiratory tract
symptoms, and the hospitalization rate for respiratory events per patient year was 0.793.
Median time to the first hospitalization for a respiratory event was 449 days (95% CI 347,
NE) with median times of 31 and 449 days for the BID- and TID-treated groups,
respectively.
Median time to IV antipseudomonal antibiotics was 247 days (95% CI 210, 287), with
similar times between the two regimen groups: 276 days for the BID-treated group (95% CI
217, 316) and 232 days for the TID group (95% CI 179, 288; Fig. 2).
Changes in Weight
Change in weight (kg) from baseline and the mean change in the CFQ-R Weight Domain
score is presented for each visit in Figure 3. Repeated courses of AZLI resulted in consistent
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weight gain, which were sustained over the 18-month period. Improvement was greater
among patients receiving TID compared to BID treatment.
Clinical Microbiology
The baseline (Visit 1) MIC50 of aztreonam for PA isolates with the highest MIC was 8 ug/ml
in both treatment groups, indicating susceptibility to aztreonam based on the parenteral
breakpoint. The baseline MIC90 of aztreonam for PA isolates with the highest MIC was 128
µg/ml in the BID treatment group and 256 µg/ml in the TID treatment group. Throughout the
study, the MIC50 of aztreonam for PA isolates with the highest MIC remained unchanged
(±2-fold change) from baseline for the BID and TID regimens (Fig. 4). There were transient
increases in MIC90 of aztreonam from baseline for PA isolates with the highest MIC in both
treatment groups (Fig. 4). More increases were observed in the BID regimen than the TID
regimen but both remained unchanged at the end of study.
As expected, sputum cultures remained positive for PA in a majority of patients. There was
no evidence for increases in the isolation of S. maltophilia, MSSA, MRSA, A. xylosoxidans
or Aspergillus spp. resulting from treatment with AZLI. Burkholderia spp. were isolated
from five patients, all in the TID group, at four different study sites. In two patients,
Burkholderia spp. were confirmed by the B. cepacia Research Laboratory and Repository
prior to the patient receiving AZLI in Studies AIR-CF1, and AIR-CF2, and AIR-CF3; the
remaining three patients had first time isolation but Burkholderia spp. confirmation was not
undertaken. None of the five patients experienced B. cepacia syndrome. All isolates of
presumptive Burkholderia spp. from four of the patients had an MIC ≤4 µg/ml to aztreonam,
indicating susceptibility to AZLI. The isolate from the remaining patient had an MIC of 32
µg/ml.
Overall increases in the prevalence of Candida spp. were observed over repeated courses of
AZLI; however, the majority of patients experienced no change in the presence or absence
of Candida spp. through the nine courses.
Adherence
Adherence was assessed by the return of empty vials as a percent of total vials prescribed,
and mean adherence was 92.0% in the BID group and 88.0% in the TID group.
DISCUSSION
The use of cyclic, suppressive inhaled antibiotic therapy with 28 days of therapy followed
by 28 days off therapy has become the standard of care for CF patients greater than 6 years
of age with chronic PA airway infection.1 AIR-CF1 and AIR-CF2 were designed to assess
the safety and efficacy of a 28-day course of AZLI in patients with varying degrees of
maintenance therapy. Results of these studies have demonstrated the safety and efficacy of
single courses of AZLI. This open-label study provided long-term data on the use of nine
courses (on/ off months) of AZLI used in conjunction with routine therapeutic regimens
prescribed by each patient’s primary CF-care provider. AIR-CF3 provides information
needed to evaluate the long-term clinical and microbiologic safety of AZLI, the durability of
AZLI’s effect on a variety of clinical health measures, and AZLI’s optimum dosing regimen
(BID vs. TID).
The safety profile observed in this study is consistent with previous AZLI studies5,6 and
with expected symptoms of patients’ underlying CF lung disease. No new safety concerns
were identified.
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The endpoints of change in FEV1 % predicted and CFQR-Respiratory scores were used to
assess different aspects of CF lung disease, pulmonary function and respiratory symptoms,
respectively. The CFQ-R is a validated CFspecific PRO measuring both generic and CF-
specific domains and directly measures patients’ perception of their respiratory symptoms.
Change from baseline on the CFQ-R-Respiratory Symptom score is categorized as
improved, stable, or worsened, depending on the magnitude and direction of change in
relation to the MCID of 4 points.11 In this study, the durability of the efficacy of AZLI was
evidenced by the sustained response in both disease-related endpoints (FEV1 and CFQ-R-
Respiratory score), as well as weight, observed over multiple courses of therapy. In the off-
treatment month, disease-related endpoints returned to near baseline but were still above
baseline values at most end-of-course visits.
In contrast to the results of repeated courses of TIS in adult patients,18 mean FEV1 %
predicted was above the baseline value at the end of each on-AZLI treatment period. In
patients with CF, progressive loss of lung function averages 1–4% predicted each year;19,20
therefore, it would be expected that patients with CF would have at least a slight decline in
FEV1 over an 18-month period rather than maintaining or improving FEV1 over this time
period. However, the absence of a placebo group limits this interpretation. Additionally, in
those patients treated with AZLI TID, mean FEV1 % predicted was above the baseline value
at the end of each off-AZLI treatment period, with the exception of the sixth and ninth
treatment courses. Thus, AZLI TID improves lung function over repeated courses of
therapy, demonstrating sustained improvement over 18 months of treatment.
It is important to note that all subjects received AZLI in addition to the routine therapeutic
regimens prescribed by each patient’s primary CF-care provider. However, improvements in
FEV1 and CFQ-R-Respiratory score only occurred when patients were being treated with
AZLI, and outcomes decreased during the off-treatment intervals. This suggests that AZLI
can achieve improvements in FEV1 and CFQ-R when added to standard treatments.
This report is the first describing weight gain as an indicator of improved overall health in a
clinical trial of an inhaled antibiotic. The relationship between lung function and nutritional
status for patients with CF has been well established,21 with malnourished patients having
worse lung function and more frequent infection with PA. In this study, repeated courses of
AZLI resulted in consistent weight gain and the CFQ-R Weight scores, both of which were
sustained in the TID group over the nine treatment courses. Again, although this was not a
placebo-controlled trial, this finding has not been demonstrated in long-term studies of
inhaled antibiotics such as TIS or colistin.
The most common cause of hospitalization during this study was the development of
symptoms consistent with CF pulmonary exacerbation; however, a median time to first
respiratory hospitalization of 449 days is notable for its length given the disease severity of
this patient population. In addition, the rate of hospitalization in this study (0.897
hospitalizations per patient year) was lower than the rate reported in a case-matched control
study of CF patients receiving standard of care therapy (1.26 hospitalizations per patient
year).22 In this retrospective, matched case control study22 between a subset of patients
receiving AZLI during the first year of AIR-CF3 versus patients with CF receiving standard
of care therapy,23 patients receiving AZLI in addition to standard of care had significantly
lower risk of hospitalization (28% less than matched-controls, P=0.020) compared to
patients receiving standard of care therapy alone.22 The addition of new therapies, such as
AZLI, may decrease the significant cost of hospitalizations and improve the overall health
care in patients with CF.
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Adherence to therapy was high in this study. Interpretation may be limited by the vial count
method used to assess compliance, as well as the fact that follow-on trials may attract more
motivated patients. Nonetheless, it is useful to note that the dosing regimen was not
associated with differences in adherence. Treatment Burden scores on the CFQ-R were
comparable between BID and TID dosing and did not change during the off-months. The
high treatment adherence observed in this study may be due to improvement in lung
function and respiratory symptoms when the patients were on treatment and due to the
portability of the eFlow nebulizer and the rapid administration of AZLI (2–3 min per dose
for AZLI administration24 vs. approximately 15–20 min per dose with TIS).18
A long-term suppressive effect of AZLI as an antipseudomonal agent was observed over the
nine treatment courses in this study. A persistent reduction in PA CFUs from baseline was
observed at each visit throughout the study, regardless of on-or off-treatment interval period.
As expected, decreases in PA CFUs consistently occurred during the on-treatment courses
throughout the study while increases toward baseline values were observed during the off-
treatment courses; this trend was more clearly observed in patients treated with AZLI TID
than BID. The fact that TID dosing appears to be a more efficacious dose is consistent with
the mode of action of aztreonam; bacterial killing is dependent on time above the MIC.25
A theoretical concern of long-term antibiotic exposure is the development of antibiotic
resistance and a possible decline in clinical efficacy. Increases in the MIC90, but not the
MIC50, of aztreonam for PA isolates with the highest MIC were transiently observed in the
BID and TID groups. The fact that increases were seen in the MIC90 but not the MIC50
suggests that bacterial growth advantages at the highest levels of resistance may confer a
selective advantage to PA isolates during exposure to high antibiotic concentrations. In
contrast, increases in resistance at lower levels, that is, MIC50, are unable to confer a
selective advantage to PA during exposure to high antibiotic concentrations. During long-
term antibiotic exposure in a disease characterized by chronic infection, aerosolized
antibiotics like AZLI ideally achieve sputum drug concentrations close to the mutant
prevention concentration (MPC) and thus suppress the development of resistance.26
Alternatively, acquisition of antibiotic resistance can confer a biologic cost to PA and this
cost can become a disadvantage in the absence of selective pressure.27 Interestingly,
immediate decreases in the MIC90 were observed during the off-treatment months in the
TID group. The reasons for this are unknown. All of these observations support the use of
75 mg AZLI TID in an intermittent 1-month on-/1-month off-treatment paradigm.
In addition, there is a theoretical concern that an alteration in the bacterial microenvironment
of the lung in a patient with CF by an antibiotic may promote growth of resistant pathogens
other than PA. Accordingly, treatment emergence of other pathogens known to colonize the
lung of patients with CF,for example, MRSAand Burkholderia spp., were intensively
monitored before, during, and after long-term use of AZLI. Presumptive intermittent
treatment-emergent infection with Burkholderia spp. was observed in three patients, but no
patients experienced B. cepacia syndrome. Moreover, it is unknown if the finding of
Burkholderia represents new acquisition of this fastidious pathogen, or in fact, the organism
was isolated more easily due to the diminution of PA bacterial density. The treatment
emergence of other pathogens was not observed, and the high prevalence of Candida spp.
observed in this study is consistent with a report demonstrating detection of Candida
albicans in sputum from 76% of adult patients with CF.28 It is possible that AZLI does not
alter the microenvironment of the CF lung enough to promote emergence of other
pathogens. Alternatively, the high concentrations of aztreonam achieved in the lung may
exert antimicrobial affects on pathogens typically not considered targets of the drug.
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The clinical management of cystic fibrosis has improved during the past 15 years, resulting
in better outcomes and greater life expectancy for patients with CF. This is in large part due
to the development of the Care Center network, and additional therapies such as dornase
alfa, azithromycin, tobramycin solution for inhalation, and, most recently, hypertonic saline.
Nevertheless, chronic airway infection with PA remains a primary source of morbidity and
mortality. The management of PA lower respiratory tract disease has historically involved
the use of repeated courses of IV antibiotics because of a lack of oral anti-pseudomonal
agents. The introduction of TIS established the concept of cyclic, suppressive inhaled
antibiotic therapy for chronic airway infection in patients with CF. Unfortunately, the
combined effects of antibiotic resistance within the environment of frequent antibiotic use,
cumulative toxicity associated with aminoglycoside use,29,30 off-cycle clinical deterioration,
and patient sensitivity have meant that TIS may not be suitable for all patients. Clearly, there
is a critical unmet medical need for additional inhaled antibiotic therapies for chronic use in
patients with CF. Such therapies will be vital in maintaining or improving lung function and
respiratory symptoms in CF patients with PA airway infection. The ideal therapy should be
safe, effective over the long term, and involve minimal burden to patients to promote
adherence to therapy. AZLI meets these criteria and represents an important new therapy for
patients with CF and chronic PA airway infection.
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AZLI Aztreonam for inhalation solution
BID Twice daily
CF Cystic fibrosis
CFU Colony forming units
CFQ-R Cystic fibrosis questionnaire-revised
CFTR Cystic fibrosis transmembrane conductance regulator gene
CI Confidence interval
FEF25–75 Forced expiratory flow from 25%to 75% of the forced vital capacity
FEV1 Forced expiratory volume in 1 sec
FVC Forced vital capacity
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MCID Minimal clinically important difference
MedDRA Medical Dictionary for Regulatory Activities
MIC Minimum inhibitory concentration
MIC50 Aztreonam concentration inhibiting the growth of 50% PA isolates
MIC90 Aztreonam concentration inhibiting the growth of 90% PA isolates
MPC Mutant prevention concentration
MRSA Methicillin-resistant Staphylococcus aureus
MSSA Methicillin-sensitive Staphylococcus aureus
n Number of patients with an observation






TID Three times daily
TIS Tobramycin inhalation solution
US United States
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Time to intravenous antipseudomonal antibiotics (days).
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Mean change (±SE) in weight (A) and mean change in CFQ-R weight domain score (B)
from baseline to study end.
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MIC50 and MIC90 of aztreonam for Pseudomonas aeruginosa isolates with the highest MIC
from each patient (µg/ml): baseline to study end.
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TABLE 1
Patient Demographics and Baseline Characteristics1
AZLI BID (N=85) AZLI TID (N=189) Total (N=274)
Country, n (%)
  US and Canada 85 (100.0) 165 (87.3) 250 (91.2)
  Australia and New Zealand 0 24 (12.7) 24 (8.8)
Age, years; mean (range) 27.3 (11.4) 29.0 (13.0) 28.5 (12.5)
Age group, n (%)
  <18 years 19 (22.4) 36 (19.0) 55 (20.1)
  ≥18 years 66 (77.6) 153 (81.0) 219 (79.9)
Male; n (%) 51 (60.0) 100 (52.9) 151 (55.1)
Weight, kg; mean (SD) 59.5 (13.3) 59.3 (15.8) 59.4 (15.1)
Body mass index, kg/m2; mean (SD) 21.3 (3.3) 21.4 (4.0) 21.4 (3.8)
CFTR genotype, n (%)2
  Homozygous for ΔF508 32 (52.5) 71 (48.0) 103 (49.3)
  Heterozygous for ΔF508 16 (26.2) 44 (29.7) 60 (28.7)
  Unidentified or other 13 (21.3) 33 (22.3) 46 (22.0)
FEV1 % of predicted value; mean (SD) 56.7 (17.5) 55.1 (15.4) 55.6 (16.1)
Patients with FEV1 ≤50% predicted value, n (%) 36 (42.4) 74 (39.2) 110 (40.1)
CFQ-R-respiratory score; mean (SD) 65.4 (16.9) 60.3 (18.5) 61.9 (18.1)
Log10 PA CFUs in sputum, mean (SD) 5.7 (2.2) 6.2 (1.9) 6.0 (2.0)
MIC of aztreonam for all PA isolates, mg/ml
  MIC50 4 4 4
  MIC90 128 128 128
  Minimum MIC ≤1 ≤1 ≤1
  Maximum MIC 2,048 > 2,048 > 2,048
  Number of isolates tested 131 288 419
1
At baseline (Visit 1, Day 0).
2
Genotyping was performed at the beginning of AIR-CF1 and AIR-CF2. Not all patients underwent CFTR genotyping; percentages were
calculated based upon the sample population (BID group, 61 patients; TID group 148 patients; total, 209 patients).
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TABLE 2







Number of tobramycin courses1 taken for all patients, n (%)
  0 40 (47.1) 93 (49.2) 133 (48.5)
  >0–1 8 (9.4) 21 (11.1) 29 (10.6)
  >1–2 6 (7.1) 23 (12.2) 29 (10.6)
  >2–3 7 (8.2) 14 (7.4) 21 (7.7)
  >3–6 9 (10.6) 14 (7.4) 23 (8.4)
  >6–10 11 (12.9) 21 (11.1) 32 (11.7)
  >10 4 (4.7) 3 (1.6) 7 (2.6)
Days on tobramycin for patients taking tobramycin
  N 45 96 141
  Mean 123.0 98.2 106.1
  Median 93 60 78
  SD 99.8 92.4 95.2
  Min 1 1 1
  Max 350 488 488
1
A tobramycin course was defined as ≥300mg dose of inhaled tobramycin for 28 days.
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TABLE 5
Summary of Hospitalization1
AZLI BID (N=85) AZLI TID (N=189) Total (N=274)
Number of patients never hospitalized, n (%) 49 (57.6) 94 (49.7) 143 (52.2)
  Withdrew early, n (%) 13 (15.3) 26 (13.8) 39 (14.2)
  Completed study, n (%) 36 (42.4) 68 (36.0) 104 (38.0)
Number of patients hospitalized at least once, n (%) 36 (42.4) 95 (50.3) 131 (47.8)
Number of patient years2 95.46 221.02 316.48
Number of hospitalizations 65 219 284
Hospitalization rate per patient year3 0.681 0.991 0.897
Total number of respiratory hospitalizations 60 191 251
Respiratory hospitalization rate per patient year 0.629 0.864 0.793
Number of hospitalization days4
  Mean (SD) 8.32 (27.59) 12.46 (21.82) 11.17 (23.78)
  Median 0.00 3.00 0.00
  Minimum 0.0 0.0 0.0
  Maximum 245.0 132.0 245.0
  n 85 189 274
  % of days hospitalized5 2.03 2.92 2.65
Time to first respiratory hospitalization (days)6
  Minimum 4 1 1
  25th percentile 204 141 161
  Median 431 449 449
  95% CI for median (294, NE) (288, NE) (347, NE)
  75th percentile NE NE NE
  Maximum 431 609 609
  Number of censored values 52 99 151
  Number of events 33 90 123
NE, not estimable.
1
Hospitalization included all hospitalizations recorded as a serious adverse event lasting more than one calendar day, or any death (excl.
hospitalizations after completion or >28 days after the date of the last dose).
2
Number of patient years is calculated as the sum of all days on study divided by 365.25.
3
Hospitalization rate is calculated as the number of hospitalizations divided by the number of patient years.
4
Number of hospitalization days for all patients (including zero days for patients who were not hospitalized).
5
Percent of days hospitalized is calculated as the sum of all hospitalization days divided by the sum of all patient study days.
6
Kaplan–Meier method is used to calculate statistics for time to first hospitalization.
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